Acute and persistent iatrogenic Cushing's syndrome after a single dose of triamcinolone acetonide.
Iatrogenic Cushing's syndrome is a well-known adverse effect of glucocorticoids. It usually develops after prolonged exposure to excessive amounts of synthetic glucocorticolds. The development of iatrogenic Cushing's syndrome (ICS) after a single and low dose of synthetic glucocorticoid is an exceptional event. Up to now, only a few number of cases have been associated with triamcinolone acetonide and they have always been related to local administration. We report, for the first time, a patient who developed ICS after a single low dose of parenterally (im) administered triamcinolone acetonide. She was a 45-yr-old woman who referred to us because of cushingoid appearance, whose hormonal determinations were suggestive of secondary adrenal insufficiency. Clinical features were developed one month after the administration of a 40 mg single-dose of im triamcinolone acetonide because of acute laryngitis. Endocrinological evaluation confirmed the hypothalamic-pituitary-adrenal (HPA) axis suppression. Eight months later, cushingoid phenotype had completely disappeared and HPA function had spontaneously recovered. We review clinical features and comment on the possible pathogenic mechanisms of this particular and new form of ICS.
Iglesias
P
P
Department of Endocrinology, Hospital General, Segovia, Spain. piglesias@hgse.sacyl.es
González
J
J
Díez
J J
JJ
D003480:Cushing Syndrome / Q000139:chemically induced*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007049:Iatrogenic Disease; D007263:Infusions, Parenteral; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000009:adverse effects*
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide